COVID-19 and the Use of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers
Source: World Health Organization (WHO). Published: 5/7/2020.
This brief summarizes the current evidence on the impact of angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers on severe acute respiratory illness due to SARS CoV-2. It addresses concerns that ACE inhibitors and angiotensin receptor blockers (ARBs) increase susceptibility to coronavirus SARS CoV-2 (the viral agent that causes the disease COVID-19) and the likelihood of severe COVID-19 illness.
(Text)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - Category: International Medicine & Public Health Source Type: news
More News: Coronavirus | COVID-19 | International Medicine & Public Health | Respiratory Medicine | SARS | WHO